Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal (MTH01)

Pharmacokinetics of Multiple Dose Methadone in Children

The purpose of this study is to learn more about how the study drug, methadone, prescribed by an infant's or child's physician as part of standard medical care, is processed in children and young adults. While this drug is used extensively in infants and children, it has not been extensively studied in this population.

Physicians do not have very much information on how long it takes for methadone to be removed from the blood circulation and passed out of the body. Physicians need more information to guide how much and how often we should give methadone to children/young adults to ensure they get the maximum effect with the minimum amount of drug. During this research study, the study team will collect information about how this drug is processed in infants and children.

Study Overview

• Status: Completed
• Conditions: Opiate Withdrawal Syndrome
• Intervention / Treatment: Drug: Methadone

Detailed Description

A total of approximately 24 to 36 infants and children will participate in this study. This study will be done at five medical centers in the United States.

Treatment will be prescribed by the infant or child's doctor and not by the study team.

Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2 to 6 years, and ages 6 to 18 years. There will be approximately 8 to 12 participants enrolled in each group. Additionally, at least 6 overweight or obese participants between ages 2-18 years will be included in this study.

Information collected from each subject's routine medical care will include:

• Participant gender, date of birth, race and ethnicity
• Pertinent medical history
• Laboratory results (blood count and chemistries) from routine testing ordered by the infant or child's regular doctor
• Medications of interest the child was given within the 72 hours prior to first dose of methadone administered after consent
• Time and dose of methadone administered to the child up to 14 days prior to enrollment

Study specific information collected will include:

• Blood sample collection to measure level of methadone
• Baseline WAT-1 score (sedation withdrawal assessment of the infant or child used to assess symptoms the child/infant may experience when opioid drugs are discontinued).

The duration of the study will be up to 10 days, comprised of a maximum 5 day treatment period a 5 day observation period.

• Study Type: Observational
• Enrollment (Actual): 26

Contacts and Locations

Study Locations

• United States
  • Florida
    • Saint Petersburg, Florida, United States, 33701
      • All Children's Hospital
  • Kansas
    • Kansas City, Kansas, United States, 64108
      • Children's Mercy Hospital
  • Michigan
    • Ann Arbor, Michigan, United States, 48109
      • C.S. Mott Children's Hospital
  • North Carolina
    • Durham, North Carolina, United States, 27701
      • Duke University Medical Center
  • South Carolina
    • Charleston, South Carolina, United States, 29425
      • Medical University of South Carolina

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 months to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Participants will be divided into 3 groups based on age, ages 3 months to 2 years, ages 2 to 6 years, and ages 6 to 18 years. There will be approximately 8 to 12 participants enrolled in each group. Additionally, at least 6 overweight or obese participants between ages 2-18 years will be included in this study.

Description

Inclusion Criteria:

• >90 days - < 18 years of age at the time of first dose of study drug
• Receiving enteral methadone as standard of care
• Signed informed consent/HIPAA documents by the parent/legal guardian and assent (if applicable)

Exclusion Criteria:

• Previous participation in the study
• Subject is receiving ECLS (Extracorporeal Life Support)
• < 36 weeks gestational age at birth for children <1 year of age at time of enrollment
• Any other condition or chronic illness that in the opinion of the Principal
• Investigator makes participation unadvised or unsafe

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cohort 1; > or = 90 days to < 2 years on enteral methadone. Dose schedule is per routine medical care.	Drug: Methadone; To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
Cohort 2; 2 years to < 6 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.	Drug: Methadone; To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
Cohort 3; 6 years to < 18 years on enteral methadone. Dose schedule is per routine medical care. Will include overweight children with BMI for age of 85 - 95 percentile, or obese children BMI for age > or = to 95 percentile.	Drug: Methadone; To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PK Parameters after multiple doses of enteral methadone	Apparent oral clearance; Apparent oral volume of distribution; Area under the curve; Absorption rate constant	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period

Secondary Outcome Measures

Outcome Measure	Time Frame
PK of methadone's primary metabolite EDDP	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period
PK of R- and S-enantiomers of methadone	Maximum of 7 PK samples based on dosing schedule collectes over a 5 day period
Correlation between plasma and DBS samples	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period
Correlation between plasma and scavenge samples	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period
Influence of CYP3A4 and CYP3B6 genetic polymorphisms on methadone PK	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period
Methadone pharmacodynamics using the WAT-1	Maximum of 7 PK samples based on dosing schedule collected over a 5 day period
Adverse events	Study days 1-5 and observational days 6-10

Collaborators and Investigators

• Sponsor: Kevin Watt
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (Actual): February 1, 2015
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: September 16, 2013
• First Submitted That Met QC Criteria: September 16, 2013
• First Posted (Estimate): September 19, 2013

Study Record Updates

• Last Update Posted (Actual): December 24, 2018
• Last Update Submitted That Met QC Criteria: December 21, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Keywords: Opiate withdrawal in children
• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Substance Withdrawal Syndrome; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Respiratory System Agents; Antitussive Agents; Methadone
• Other Study ID Numbers: Pro00044082; HHSN27500021 (Other Identifier: NICHD)